文献速递乳腺癌

维利帕尼联合卡铂-紫杉醇一线治疗HER2阴性胚系BRCA突变乳腺癌的疗效与安全性:随机临床试验亚组分析

Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.
PubMed 文献 · Eur J Cancer · 2021-07-06

BROCADE3预设亚组分析评估维利帕尼联合卡铂-紫杉醇在无既往转移性化疗的胚系BRCA突变HER2阴性乳腺癌患者中的疗效与安全性。

要点

  • 一线亚组中维利帕尼联合方案中位PFS 16.6个月,优于对照组13.1个月。
  • 2年无进展生存率36% vs 23.2%,3年27.9% vs 13.3%。
  • 因非进展不良事件停药率维利帕尼组9.1%,对照组5.8%。

核心结论

  • 维利帕尼联合卡铂-紫杉醇在无既往转移性化疗的胚系BRCA突变HER2阴性乳腺癌患者中带来持久疾病控制,提示早期线治疗获益。

研究设计与样本

  • BROCADE3随机临床试验的预设亚组分析,评估无既往转移性化疗患者的疗效与安全性。

主要发现

  • 2年无进展生存比例维利帕尼组36% vs 对照组23.2%,3年27.9% vs 13.3%。
  • 因非进展不良事件导致研究药物停药的患者维利帕尼组25例(9.1%),对照组8例(5.8%)。

临床怎么用

  • 对于无既往转移性化疗的胚系BRCA突变HER2阴性乳腺癌患者,可考虑维利帕尼联合卡铂-紫杉醇一线治疗以延长PFS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Addition of veliparib to carboplatin-paclitaxel, with continuation of veliparib monotherapy if carboplatin-paclitaxel was discontinued, improved progression-free survival (PFS) in patients with germline BRCA-associated locally advanced/metastatic HER2- breast cancer and ≤2 lines of previous cytotoxic therapy for metastatic disease in BROCADE3. A pre-planned subgroup analysis evaluated efficacy and safety in patients without previous cytotoxic therapy for metastatic disease. METHODS: Patients were randomised 2:1 to receive veliparib (120 mg orally BID) or placebo on days -2 to 5. Carboplatin (AUC 6) was administered on day 1, and paclitaxel (80 mg/m2) on days 1, 8 and 15 (21-day cycles). Patients discontinuing carboplatin-paclitaxel for reasons besides progression could continue veliparib/placebo monotherapy (300 mg BID, increasing to 400 mg BID if tolerated) until progression. The primary end-point was PFS assessed by investigator. RESULTS: Of 509 patients in the intention-to-treat population (98.6% female; mean age 47, standard deviation 11), 413 (81%) had no previous cytotoxic therapy for metastatic disease (274, veliparib; 139, placebo). In the first-line subgroup, median PFS was 16.6 months (95% confidence interval [CI] 13.4-18.7) versus 13.1 months (95% CI 11.4-14.5) for the veliparib versus control groups (hazard ratio 0.70, 95% CI 0.54-0.89, P = .004). More patients were alive and progression-free at 2 years (36% versus 23.2%) and 3 years (27.9% versus 13.3%) in the veliparib versus control group. Adverse events unrelated to progression leading to study drug discontinuation occurred in 25 (9.1%) and 8 (5.8%) patients. CONCLUSIONS: Veliparib with carboplatin-paclitaxel led to durable disease control among first-line patients, suggesting a benefit of this treatment approach in early lines. CLINICAL TRIAL REGISTRATION: NCT02163694.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Arun BK, Han HS, Kaufman B, et al. Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. Eur J Cancer. 2021. PMID: 34243076. doi:10.1016/j.ejca.2021.05.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。